Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
However, rare but serious risks also exist
Cornell S (2020) A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents
--- Practical Example: BPC-157 + TB-500 + GHK-Cu Vials (pre-reconstituted, in fridge): BPC-157: 5mg vial + 2.5mL BAC = 2mg/mL TB-500: 10mg vial + 2mL BAC = 5mg/mL GHK-Cu: 50mg vial + 5mL BAC = 10mg/mL Target doses: BPC-157: 250mcg draw 12.5 units (100u syringe) TB-500: 500mcg draw 10 units GHK-Cu: 1mg draw 10 units Total draw: ~32.5 units = 0.325mL very comfortable for a single subQ injection
This is precisely the pattern that correlates with reduced cardiovascular risk, reduced diabetes risk, and improved metabolic function
Dont try to compensate by increasing the next dose
